Masakazu Toi – författare

This book presents a comprehensive overview and outlook for the future of indocyanine green (ICG) fluorescence navigation surgery, which is attracting clinical interest as a safe and less invasive procedure not only in detecting cerebral vessels, coronary arteries, and biliary trees, but also in identifying sentinel lymph nodes in cancer. The book starts with the characteristics of ICG and photodynamic cameras/endoscopes, followed by detailed descriptions of the applications of ICG fluorescence imaging in various areas such as ocular surgery, neurosurgery, cardiovascular surgery, and plastic surgery. It also covers identifying sentinel lymph nodes in breast cancer as well as cancers of the gastrointestinal tract, and provides valuable information for hepato-biliary-pancreatic surgeons, such as identifying tattooing of liver segments and bile leakage. Written entirely by experts in their respective areas, ICG Fluorescence Imaging and Navigation Surgery offers an essential resource for surgeons operating on cancers and vascular disorders in the brain and cardiovascular systems and in plastic surgery.

This book deals with the essential factors in the personalization of treatment for primary breast cancer. These include host issues, lymph node surgery, radiation therapy, and preoperative systemic treatment requiring specialized knowledge, multidisciplinary care experience, techniques, and research. Locoregional treatment in conjunction with systemic treatments is another important factor, with options for local therapy significantly affected by genetic BRCA mutation. Axillary treatment issues have become top priorities in recent primary breast cancer care, and these are highlighted in the book’s presentation of technological advances in lymph node mapping and diagnosis, axillary clearance in patients with nodal metastasis, and the role of axillary surgery. Attention is also given to locoregional treatment after preoperative systemic therapy. Because therapeutic impact differs depending upon biological characteristics such as tumor subtype, local therapy should be based both on tumor biology and on therapeutic response in parallel. Associated translational research and mathematical prediction tools such as nomograms also are introduced. This book provides the essence of primary breast cancer care, particularly its individualization with novel therapeutic concepts and strategies, and will greatly benefit physicians and clinical investigators in breast cancer institutions.

This book provides readers with the most up-to-date practical information on breast cancer screening. Since breast cancers are highly heterogeneous, time to clinical onset from the initial carcinogenesis differs diversely between cancers. Pathological germline variants and driver mutations cause a high lifetime risk of breast cancer. The lifetime risks are various according to what genes are pathologically dysfunctional. Integrated omics and imaging technologies have established varying tumour characteristics. Thus, this book suggests that a more individualised scheme is required to improve breast cancer screening.

A key aim is to demonstrate how multiple diagnostic imaging modalities such as mammography, ultrasonography, MRI, PET and dbPET improve breast cancer screening accuracy. Mammography screening alone may have a limited impact on breast cancer risk prediction. These issues are crucial to discuss. Clinical experts recommend that new modalities be incorporated for women with dense breasts, like ultrasonography, dynamic mammography, MRI and maybe breast-dedicated PET. Topics on these modalities are going to be summarized in this book.  An in-depth review of these modalities is summarised in this book. In addition, new diagnostic modalities, including risk assessment tools, multi-cancer early detection tests using liquid biopsy, the role of protein biomarkers in breast cancer risk screening, challenges, and hopes for future advances, are also covered in this book.

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.